ASBP
Aspire Biopharma Holdings, Inc.
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.10
- 시가총액
- 30,981
- 배당수익률
- -
- 베타
- 0.21
- 1개월 수익률
- -84.73%
- 3개월 수익률
- -87.45%
- 6개월 수익률
- -98.68%
- 1년 수익률
- -98.60%
- 2년 수익률
- -
- 5일 평균거래량
- 1356321
- 60일 평균거래량
- 454069
- 1년 평균거래량
- 128456
- 5d/60d 거래량 비율
- 2.99×
- 60d/1y 거래량 비율
- 3.53×
- 변동성(60일, 연환산)
- 224.48%
- BB 스퀴즈 스코어
- 3.65
- SMA50 비율
- 0.24
- SMA200 비율
- 0.02
- RSI (14)
- 32
- 20일 수렴도
- 0.87
- 52주 최고
- 847.68
- 52주 최저
- 4.65
- 고점 대비
- -99.35%
- 저점 대비
- 18.19%
펀더멘털 갱신: 2026-05-10T07:45:23+00:00 · 시세 갱신: 2026-05-10T06:08:49+00:00
회사 정보
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.